Table 3.
Quantitative effect of NPSR1 SNPs of interest on physiological endpoints.
| rs2609234 | rs714588 | rs1379928 | rs10278663 | rs740347 | rs324981 | rs6972158 | |
|---|---|---|---|---|---|---|---|
| Allele tested | A | A | T | A | C | A | G |
| GE T ½ | |||||||
| CF6 | −27.1% | ||||||
| GC24 | +15.5% | +16.2% | +10.1% | ||||
| GC48 | +16.0% | +11.1% | +8.1% | +10.0% | |||
| MT Vol | |||||||
| Aggregate Score | +23.1% | +18.6% | |||||
| Fast GVol | |||||||
| Av Fed GVol | −5.7% | ||||||
| Delta Vol | |||||||
| Compliance Pr50 | |||||||
| Gas at 36 mm Hg | +22.5% | ||||||
| Urgency at 36 mm Hg | +9.9% | −5.5% | |||||
| Pain at 36 mm Hg | +20.7% | +24.7% | +19.9% |
NOTE: The direction of the relative contribution of tested alleles to each variable is expressed as mean percent increase (+) or decrease (−), calculated from the difference between carriers and non-carriers over the entire sample. Only effects for significant (p < 0.05) associations are reported, and those withstanding FDR correction for multiple tests (as reported in Table 1) are underlined. Abbreviations used to define variables are the same as from previous tables.